Gastroenterology: Hormone therapy increases the risk of severe neo-coronary pneumonia infection in patients with inflammatory bowel disease.

The impact of Coronary Virus Disease (Covid-19) on patients with inflammatory bowel disease (IBD) in 2019 has not been sufficiently studied.
recently analyzed the clinical process after infection with Covid-19 in IBD patients and assessed the effects of demographic, clinical characteristics, and immunosuppressant therapy on Covid-19 results.
SECURE-IBD study, data on IBD patients with new coronavirus infections were collected, age-standardized mortality rates were calculated in IBD patients, and multivariable logic regression was used to identify factors associated with severe Covid-19, including intensive care unit hospitalization, ventilator use, and/or death.
study collected the medical records of 525 patients in 33 countries, with an average age of 43 years and 53 per cent of men.
37 patients were clinically divided into severe COVID-19 (7%), 161 patients were hospitalized (31%) and 16 died (mortality rate was 3%).
data from China, Italy and the United States.
risk of death from neo-crown pneumonia in IBD patients was 1.8, 1.5 and 1.7, respectively.
Factors associated with the development of severe neo-coronary pneumonia in patients with IBD include: old age (adjusted ratio ratio of 1.94), more than 2 co-diseases (2.9), systemic hormone therapy (6.9), and treatment with lysolamine or 5-amino water liganate (3.1).
treatment with tumor necrosis factor antagonists does not increase the risk of IBD patients developing severe neo-coronary pneumonia (0.9).
study found that patients with inflammatory bowel disease who were elderly and receiving systemic hormone therapy had a higher risk of developing severe neo-coronary pneumonia, while treatment with tumor necrosis factor antagonists was safer.
.